Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Enrolling by invitationEarly Phase 1 A Single-center, Single-arm Clinical Study of the Efficacy and Safety of INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer
This is a clinical study on the use of iNK cells for the treatment of small cell lung cancer.
/ Not yet recruitingEarly Phase 1 Single-center and Single-arm Clinical Study of INK Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
100 Clinical Results associated with Guangzhou Ruixin Biotechnology Co., Ltd.
0 Patents (Medical) associated with Guangzhou Ruixin Biotechnology Co., Ltd.
100 Deals associated with Guangzhou Ruixin Biotechnology Co., Ltd.
100 Translational Medicine associated with Guangzhou Ruixin Biotechnology Co., Ltd.